Investors

Press Releases

Overview
Press Releases
Events + Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
News Alerts

Recent Press Releases

Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval
April 13, 2021

Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021

Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
March 03, 2021

Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors
February 23, 2021

Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021

Vallon Pharmaceuticals Announces Pricing of Initial Public Offering
February 09, 2021

Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting
January 19, 2021

Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting
January 08, 2021

Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR
November 09, 2020

Vallon Newsroom